Skip to main content
. 2021 Feb 9;41(4):914–916. doi: 10.1177/0271678X21992664

Figure 1.

Figure 1.

Time course of stroke and potential blood biomarkers. Current measures of stroke consist of clinical assessments and neuronal imaging to confirm a stroke and initiate enzymatic thrombolysis (tPA) and/or mechanical thrombectomy (MT) treatment. The therapeutic window of the treatments is 4–6.5 hours following stroke. Several days after stroke rehabilitative training begins and can continue for months-years. Regular measures of motor and cognitive abilities are performed to determine long-term effects of stroke e.g. NIHSS, MMSE, mRS. Types of Biomarker: To measure the risk to develop a disease (risk prediction); To confirm the presence of a disease or identify subtypes (diagnosis); to identify probability to develop a clinical event in patients with a disease (prognosis); to predict probability to develop any effect as consequence of clinical intervention (prediction); to monitor the status of a disease and the response to an intervention (monitoring). tPA: tissue plasminogen activator; MT: mechanical thrombectomy, NIHSS: National Institutes of Health Stroke Scale; mRS: modified Rankin Scale; MMSE: Mini-Mental State Examination.